Evidence map›Paper›PMID 38543900›Full record

ArticleVaccines2024

Toward a SARS-CoV-2 VLP Vaccine: HBc/G as a Carrier for SARS-CoV-2 Spike RBM and Nucleocapsid Protein-Derived Peptides.

Ivars Petrovskis, Dace Skrastina, Juris Jansons, Andris Dislers, Janis Bogans, Karina Spunde, Anastasija Neprjakhina, Jelena Zakova, Anna Zajakina, Irina Sominskaya

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ivars PetrovskisLatvian Biomedical Research and Study Centre, Ratsupites 1, LV-1067 Riga, Latvia.
Dace SkrastinaLatvian Biomedical Research and Study Centre, Ratsupites 1, LV-1067 Riga, Latvia.
Juris JansonsLatvian Biomedical Research and Study Centre, Ratsupites 1, LV-1067 Riga, Latvia.ORCID 0000-0003-0845-4392
Andris DislersLatvian Biomedical Research and Study Centre, Ratsupites 1, LV-1067 Riga, Latvia.
Janis BogansLatvian Biomedical Research and Study Centre, Ratsupites 1, LV-1067 Riga, Latvia.
Karina SpundeLatvian Biomedical Research and Study Centre, Ratsupites 1, LV-1067 Riga, Latvia.
Anastasija NeprjakhinaLatvian Biomedical Research and Study Centre, Ratsupites 1, LV-1067 Riga, Latvia.
Jelena ZakovaLatvian Biomedical Research and Study Centre, Ratsupites 1, LV-1067 Riga, Latvia.
Anna ZajakinaLatvian Biomedical Research and Study Centre, Ratsupites 1, LV-1067 Riga, Latvia.ORCID 0000-0002-4753-1103
Irina SominskayaLatvian Biomedical Research and Study Centre, Ratsupites 1, LV-1067 Riga, Latvia.ORCID 0000-0002-1932-369X
Latvian Biomedical Research and Study Centre · LV

Funding

Latvian Council of Science lzp- 2021/1-0059
6 · The paper itself

Abstract

Virus-like particles (VLPs) offer an attractive possibility for the development of vaccines. Recombinant core antigen (HBc) of Hepatitis B virus (HBV) was expressed in different systems, and the

Indexed as

HBcHBV genotype GimmunogenicitySARS-CoV-2 epitopesVLP

Identifiers

PMID38543900
PMCPMC10974900
OpenAlexW4392377107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.